Format

Send to

Choose Destination
J Clin Virol. 2013 Jun;57(2):157-60. doi: 10.1016/j.jcv.2013.02.005. Epub 2013 Mar 6.

First therapeutic use of Artesunate in treatment of human herpesvirus 6B myocarditis in a child.

Author information

1
Department of Pediatric Cardiology, Children's Heart Centre, Skåne University Hospital, Lund, Sweden. nina.hakacova@gmail.com

Abstract

BACKGROUND:

Human herpesvirus 6 (HHV-6) is an important cause of fulminant or acute viral myocarditis. However, insufficiency of standard antiviral treatment against HHV-6 is an emerging problem.

OBJECTIVES:

To describe the case of child with HHV-6 myocarditis who was treated by unloading with a left ventricular assist device and Artesunate.

STUDY DESIGN:

Case report supported by histological and viral diagnoses via a combination of histology/immunohistochemistry and polymerase chain reaction techniques performed on cardiac tissues before and after treatment.

RESULTS:

Following therapeutic intervention, the clinical status and heart function improved. Endomyocardial biopsies revealed decreased levels of HHV-6B DNA in the myocardium and the disappearance of histological findings in support of lymphocytic myocarditis. Left ventricular assist device could be explanted. No adverse effects of Artesunate were noted.

CONCLUSIONS:

In addition to existing heart failure treatments, Artesunate can be considered as an effective candidate for clinical use in cases of HHV-6B associated myocarditis.

PMID:
23473961
DOI:
10.1016/j.jcv.2013.02.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center